Monthly Archives: April 2021

In patients with active psoriatic arthritis (PsA), treatment with tofacitinib is associated with long-term efficacy (up to 36 months) and safety (up to 48 months), according to results of an analysis published in Lancet Rheumatology.

Researchers sought to evaluate the long-term safety and efficacy of tofacitinib in adult patients with active PsA.

The open-label, long-term extension study the final analysis of the Oral Psoriatic Arthritis Trial (OPAL) Balance study (ClinicalTrials.gov Identifier: NCT01976364) was conducted at 124 centers in 16 countries.

Continue Reading

Primary study endpoints included incidence of clinical laboratory abnormalities, changes from baseline in laboratory parameters up to 48 months in patients from the long-term extension study and substudy, and incidence and severity of adverse events (AEs). Eligible patients in OPAL Balance study had also participated in the OPAL Broaden or the OPAL Beyond phase 3 trials.

In the OPAL Balance study, all participants received open-label tofacitinib 5 mg twice daily, with dose escalations to 10 mg twice daily at month 1 for inadequate symptom control, as well as reductions to 5 mg twice daily thereafter for safety. All participants could continue to receive concomitant treatment with specific conventional synthetic disease-modifying antirheumatic drugs. Eligible patients could also enter the randomized, double-blind methotrexate withdrawal substudy, in which participants received open-label tofacitinib 5 mg twice daily plus either masked methotrexate or masked placebo.

A total of 686 participants were enrolled in OPAL Balance study, between February 17, 2014, and March 28, 2016, who received treatment with tofacitinib and were enrolled in the all-tofacitinib group for the safety and efficacy analyses. Ultimately, 66% (n=453) of participants completed this study and 34% (n=233) discontinued their participation in either the long-term extension study or the methotrexate withdrawal substudy. In the all-tofacitinib group, the mean duration of tofacitinib treatment was 794.6 days and the total duration of treatment was 1492.4 person-years in the long-term extension study. Mean age of the participants in the all-tofacitinib group was 48.8 years; 54% of the participants were women; mean duration of PsA was 7.6 years.

Up to month 48, 84% (n=574) of participants reported the occurrence of all-cause AEs, with 17% experiencing serious AEs and 11% discontinuing treatment because of an AE. Overall, 6 patients died, among whom 1 was within the risk period (incidence of death was 0.1 patients with events [95% CI, 0.0-0.3] per 100 person-years). Incidences of AEs of special interest, which was defined as the number of patients with events per 100 person-years, included the following: 1.7 (95% CI, 1.2-2.5) for herpes zoster; 1.0 (95% CI, 0.6-1.6) for serious infections; 0.4 (95% CI, 0.1-0.8) for opportunistic infections; 0.7 (95% CI, 0.4-1.2) for malignancies other than nonmelanoma skin cancer (NMSC); 0.9 (95% CI, 0.5-1.5) for NMSC; 0.2 (95% CI, 0.1-0.6) for major adverse cardiovascular events; 0.4 (95% CI, 0.1-0.8) for arterial thromboembolism; and 0.1 (95% CI, 0.0-0.3) for pulmonary embolism. Efficacy was sustained for up to 36 months.

A major limitation of the current study included the lack of generalizability to patients who are new to tofacitinib treatment. Further, the long-term extension study was open-label and had no placebo group; the analyses used observed values; and evaluations of dose-related effects were conducted post hoc.

Researchers concluded that the data reported in this trial support the use of tofacitinib in the long-term treatment of active [PsA].

Disclosure: This analysis was supported by Pfizer. Please see the original reference for a full list of authors disclosure.

Nash P, Coates LC, Fleishaker D, et al. Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. Lancet Rheumatol. 2021;3:270-283. doi:10.1016/S2665-9913(21)00010-2

See the original post:
Long-Term Efficacy and Safety of Tofacitinib in Patients With Psoriatic Arthritis Analyzed - Rheumatology Advisor

The promising drug pipeline will further propel the demand for the advanced medication in the long run. This trend is expected to propel over the forecast period as the prevalence rate has been increasing. Hence, a thorough understanding approach is required for disease management, which would certainly help manage childhood psoriasis better. However, lack of awareness in emerging economies and insufficient research funding may hamper the market.

The global Pediatric Psoriasisreport studies the prudent tactics undertaken by the leading market players, such as partnerships and collaborations, mergers & acquisitions, new product launches, and joint ventures. The global Pediatric Psoriasisis highly consolidated due to the presence of a large number of companies across this industry. These companies are known to make hefty investments in research and development projects. Also, they control a considerable portion of the overall market share, thus limiting the entry of new players into the sector.

To get leading market solutions, visit the link below: https://www.emergenresearch.com/industry-report/pediatric-psoriasis-market

The global Pediatric Psoriasisstudy covers the current COVID-19 scenario that has turned the global business sphere upside down. The coronavirus has resulted in a major economic downturn worldwide, while also adversely impacting the growth of this industrial sector. The pandemic has brought about drastic changes in market conditions. Therefore, the latest report elaborates on the rapidly changing market scenario and conducts preliminary, as well as the future assessment of COVID-19 impact on the market. Moreover, the document contains a broad analysis of prime aspects of the market, with expert opinions on the current market standing and historical data.

Key highlights of the Global Pediatric Psoriasisreport:

See the original post:
Pediatric Psoriasis Market Compound Annual Growth Rate of 21.38% | Market Trend Growing demand for biologics and natural remedies for child...

Up Market Research (UMR) has included a latest report on the Global Psoriasis Therapeutics Market into its archive of market research studies. The report is an amalgamation of detailed market overview based on the segmentations, applications, trends and opportunities, mergers and acquisitions, drivers, and restraints. The report showcases the current and forthcoming technical and financial details of the Psoriasis Therapeutics market. The research study attracts attention to a detailed synopsis of the market valuation, revenue estimation, and market statistics. The study on the emerging trends in the global and regional spaces on all the significant components, such as market capacity, cost, price, demand and supply, production, profit, and competitive landscape. The report also explores all the key factors affecting the growth of the global market, consisting of the demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

Some of the major companies that are covered in this report:

Astellas Pharma Inc.AstraZeneca plcBoehringer Ingelheim GmbHF. Hofffmann-La RocheGlaxoSmithKline plcMerck & Co.Inc.Valeant Pharmaceuticals InternationalInc.Biocon LimitedEli Lilly and CompanyG & W Laboratories Inc.

*Note: Additional companies can be included on request

Get a free exclusive sample report of Psoriasis Therapeutics market @ https://www.upmarketresearch.com/home/requested_sample/11821

Impact of COVID-19

The report also talks about the impact of the ongoing global crisis i.e., COVID-19 on the Psoriasis Therapeutics market and explains how the future is going to unfold for the global market. Our analysts have researched thoroughly about the effects of the pandemic on the global economy. The outbreak has directly affected production and demand disrupted the demand and supply chain. The report also computes the financial impact on firms and financial markets. Up Market Research (UMR) has accumulated insights from several delegates of the industry and got involved in the primary and secondary research to offer the clients data & strategies to combat the market challenges during and after the COVID-19 pandemic.

Highlights of the report:

Our research analysts who are the building blocks of the company have worked extensively to fabricate the research report which will give that extra edge to our clients business in the competitive market. The market research report can be customized as per you and your needs. This means that Up Market Research (UMR) can cover a particular product, application, or can offer a detailed analysis in the report. You can also buy a separate report for a specific region.

You can buy the complete report in PDF format: @ https://www.upmarketresearch.com/buy/psoriasis-therapeutics-market

The market scenario is likely to be fairly competitive. To analyze any market with simplicity the market is fragmented into the following segments:

By Applications:

OralParenteralTopical

By Types:

TNF InhibitorsPDE4 InhibitorsInterleukin BlockersOthers

By Regions:

Segmenting the market into smaller components helps in analyzing the dynamics of the market with more clarity. Another key component that is integrated into the report is the regional analysis to assess the global presence of the Psoriasis Therapeutics market. You can also opt for a yearly subscription of all the updates on the Psoriasis Therapeutics market.

If you have any questions on this report, feel free to reach us! @ https://www.upmarketresearch.com/home/enquiry_before_buying/11821

Below is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Psoriasis Therapeutics Market Overview

Global Psoriasis Therapeutics Market Analysis and Forecast by Type

Global Psoriasis Therapeutics Market Analysis and Forecast by Application

Global Psoriasis Therapeutics Market Analysis and Forecast by Sales Channel

Global Psoriasis Therapeutics Market Analysis and Forecast by Region

North America Psoriasis Therapeutics Market Analysis and Forecast

Latin America Psoriasis Therapeutics Market Analysis and Forecast

Europe Psoriasis Therapeutics Market Analysis and Forecast

Asia Pacific Psoriasis Therapeutics Market Analysis and Forecast

Asia Pacific Psoriasis Therapeutics Market Size and Volume Forecast by Application

Middle East & Africa Psoriasis Therapeutics Market Analysis and Forecast

Competition Landscape

About Up Market Research (UMR):

Up Market Research (UMR) has a vast experience in making customized market research reports in a number of industry verticals. We strive for complete client satisfaction. We cover in-depth market analysis, which consists of stipulating lucrative business strategies, especially for the new entrants and the emerging players of the market. Our team makes sure that each report goes through intensive primary, secondary research, interviews, and consumer surveys before final dispatch.

We invest in our analysts to ensure that we have a full roster of experience and expertise in any field we cover. Our team members are selected for stellar academic records, specializations in technical fields, and exceptional analytical and communication skills. We also provide ongoing training and knowledge sharing to keep our analysts tapped into industry best practices and loaded with information.

Contact Info UpMarketResearchName Alex MathewsEmail [emailprotected]search.comWebsite https://www.upmarketresearch.comAddress 500 East E Street, Ontario, CA 91764, United States.

https://neighborwebsj.com/

Read the original post:
Psoriasis Therapeutics Market 2021 Will Reflect Significant Growth in Future with Size, Share, Growth, and Key Companies Analysis- Astellas Pharma...

C4X Discoverys business model, of out-licensing rather than developing projects in house, looks like it is starting to deliver. This weekthe UK group announced a 414m ($494m) biodollar licensing deal with Sanofi for its oral preclinical IL-17A inhibitor programme. While the upfront payment of 7m was slightly more modest, landing a big name partner was enough help drive shares in the UK biotech up by 8%.

The deal with Sanofifollows an agreement with Indivior in 2018, worth$10m up front,and is all part of a plan by C4X's chief executive, Clive Dix, to hand off assets before they even hit the clinic. Speaking to Evaluate Vantage he said: We think our technology is best placed finding molecules, getting good quality starting points, taking them as far as we can as a candidate and out licensing.

This approach runs counter to that of many UK biotechs, which have traditionally focused on discovering single products usually due to funding constraints and trying to commercialise them. It is an method that Mr Dix thinks might have held some companies back.

We try to avoid thisbecause if your first molecule fails it kills the company, and if it doesnt it changes the company completely, because you then become that molecule, he says.

Shifting the risk

In C4Xs deal with Sanofi, the French company will take on all of the risks and cost of commercialising the oral IL-17 inhibitor, which will be developed initially in psoriasis.

The current leading IL-17 inhibitor forpsoriasis, Novartis's Cosentyx,sold almost $3bn for this use last year, but as a MAb it tends to be reserved for more severe forms of the disorder.

C4X is hoping its small molecule approach will allow the treatment model to move back to milder forms of psoriasis, giving themand Sanofia bigger share of the market, which is forecast to hit $32bn in 2026, according to Evaluate Pharma.

Alongside the 7m upfront payment from Sanofi, C4X is in line for a further 11m if a candidate enters the clinic. The money will be ploughed back into C4Xs current pipeline, which includes a Nrf-2 activator and an oral 47 integrin inhibitor programme, in the hopes of finding partners for these assets. Mr Dix is also on the lookout for another project to bring in to keep the number of internal programmes running at about five.

The deal with Sanofi has brought some renewed investor interest in the company, whose shares had hit historic lows earlier this year. But at 43p the stock isstill a long way off the 130p it hit in 2016, making C4X look relatively cheap.

Staying single

ButMr Dix is not interested in selling anytime soon. The end goal is to make this a sustainable drug discovery engine. Roll forward five or six years and if we have done another three deals, then you have an expectation of revenues coming in all the time and its a fairly chunky business.

And it is gaining scale through deals that generate revenues that Mr Dix hopes will keep C4X independent. All the little [UK] companies that have done well have been bought in the main by an American [group]and disappeared, he says.

Mr Dix blames theinability of UK firms to grow independently on the age-old problem of lack of funding in the country. If there was the right sort of risk-reward funding then we might build a company that becomes the next Celltech or the next Amgen, but the funding model doesnt work at the moment, it just doesnt want to put big money behind clinical development candidates, he says.

As such C4X will have to keep signing more deals with big pharma if it wants to buck the UK biotech trend.

Read more from the original source:
C4X shows being early to the party can bring success - Vantage

Jess Wright has admitted that dealing with her uncle's tragic death has made her psoriasis get worse.

The former TOWIE star, 35, has always been honest with fans about her skin condition - something she's been battling for 14 years.

And it seems as though it's only gotten worse after she was forced to endure major heartbreak when her uncle Edward died from coronavirus.

The reality TV star said that although it's been frustrating to see her psoriasis worsen during the last "really rubbish few months", Jess admits she's glad she was honest with fans.

"My psoriasis has got a lot worse because of the pandemic. With my uncle and all the stress of the past year, it's flared up. It's been a really rubbish few months with everything that's gone on," she told new! mag.

"I'm really glad I did share it. So many people appreciate my openness and it's important to keep it real," Jess added.

Psoriasis is an autoimmune disease that turns skin red, dry and itchy.

Jess last month opened up about how "broken" her beloved uncle's death has left her.

"Broken," Jess began in her social media tribute.

"It still doesnt seem real that youre gone. You leave the biggest hole in our familys heart because you were everything that represented the Wrights & you did everything you could to keep us together as much as possible as it meant so much to you.

Jess continued: "Not just my uncle, but like a second dad to me in so many ways."

She went on: "The best grandad, dad, husband, son & uncle there ever could be. Your smile lights up every room & you are the glue that held us all together.

"I will look after nanny & grandad just like you did so well, I promise. And your children who I love like my own brothers and sister.

"I miss you so much already Ed, see you again some day. Love you uncle Eddie," Jess concluded in her touching message.

Do you have a story to sell? Get in touch with us at webcelebs@trinitymirror.com or call us direct 0207 29 33033

Original post:
Jess Wright says coping with heartache of uncle's tragic death made her psoriasis worse - Mirror Online